Home / Pharmaceutical / The Pharmaceutical Market: Kazakhstan

The Pharmaceutical Market: Kazakhstan

Published: Dec 2014 | No Of Pages: 96 | Published By: Espicom

Product Synopsis

Kazakhstan Pharmaceuticals & Healthcare Report
 
Kazakhstan ' s pharmaceutical market remains the most accessible, transparent and, from a legislative point of view, progressive in Central Asia. In terms of market size, its potential is limited by its relatively small population (15mn) and logistical challenges. In the short term, Kazakhstan ' s market development is driven by a balanced policy of import substitution and integration into regional (Customs Union) and global (World Trade Organisation) systems. Over the longer term, the country could leverage its favourable business environment and regional ties to supply neighbouring states, such as Uzbekistan, Kyrgyzstan, Turkmenistan and Tajikistan, all of which have growing populations and lack domestic production capacity. The country ' s government is in the mid dle of implementing an industrial development policy for pharmaceuticals and three of the top five producers - Chimpharm, Nobel and Global Pharm - are now controlled by foreign investors. The primary threat to the industry and foreign invest ment is the spectre of political instability (and consequent economic instability) that may occur when President Nursultan Nararbayev, who has led the country since Soviet times, leaves the scene . This is especially relevant as no heir is yet in place.
 
Headline Expenditure Projections
  • Pharmaceuticals: KZT218.1bn (US$1.46bn) in 2012 to KZT245.4bn (US$1.65bn) in 2013; up 12.5% in local currency terms and 12.8% in US dollar terms. Forecast adjustedupslightly due to updatedexchangerateforecasts.
  • Healthcare: KZT1,165.2 (US$7.82bn) in 2012 to KZT1,330.3bn (US$8.95bn) in 2013; up 14.2% in local currency terms and 14.5% in US dollar terms. Forecast adjustedupslightly due to updatedexchangerateforecasts.
  • Medical Devices: KZT93.35bn (US$630mn) in 2012 to KZR102.3bn (US$690mn) in 2012; up 9.5% in local currency terms and 9.8% in US dollar terms.
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT9
Industry Forecast11
Pharmaceutical Market Forecast11
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Kazakhstan 2010-2018)12
 
Healthcare Market Forecast13
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Kazakhstan 2010-2018)14
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Kazakhstan 2010-2018)15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Kazakhstan 2010-2018)15
 
Prescription Drug Market Forecast16
 
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Kazakhstan 2010-2018)17
 
Patented Drug Market Forecast17
 
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Kazakhstan 2010-2018)18
 
Generic Drug Market Forecast19
 
Table: Generics Drug Market Indicators, Historical Data And Forecasts (Kazakhstan 2010-2018)20
 
OTC Medicine Market Forecast21
 
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Kazakhstan 2010-2018)22
 
Pharmaceutical Trade Forecast23
 
Table: Pharmaceutical Trade Data And Forecasts (Kazakhstan 2012-2018)24
Table: Pharmaceutical Trade Data And Forecasts local currency (Kazakhstan 2012-2018)24
 
Key Risks To BMI's Forecast Scenario25
Macroeconomic Forecasts26
Economic Analysis26
Industry Risk Reward Ratings30
Central And Eastern Europe Risk/Reward Ratings30
Kazakhstan Risk/Reward Ratings37
Rewards37
Risks38
Market Overview40
Industry Trends And Developments42
Epidemiology42
Healthcare Sector43
Healthcare Sector Financing45
Domestic Pharmaceutical Industry46
Wholesale And Retail50
Foreign Pharmaceutical Industry51
Clinical Trials54
Regulatory Development55
Intellectual Property Environment57
Pricing And Reimbursement Regime58
Competitive Landscape62
Company Profile65
Chimpharm65
Romat67
Novartis69
Sanofi71
GlaxoSmithKline73
Nycomed75
Merck & Co77
Pfizer78
Ranbaxy80
Demographic Forecast82
 
Table: Kazakhstan's Population By Age Group, 1990-2020 ('000)83
Table: Kazakhstan's Population By Age Group, 1990-2020 (% of total)84
Table: Kazakhstan's Key Population Ratios, 1990-202085
Table: Kazakhstan's Rural And Urban Population, 1990-202085
 
Glossary86
Methodology88
Pharmaceutical Expenditure Forecast Model88
Healthcare Expenditure Forecast Model88
Notes On Methodology89
Risk/Reward Ratings Methodology90
Ratings Overview91
 
Table: Pharmaceutical Risk/Reward Ratings Indicators91
 
Indicator Weightings92
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +